The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL-Reference-Cited by-同舟云学术

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL

Published:2023-05 Issue:5 Volume:29 Page:311.e1-311.e7
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Rubinstein Jeremy D.^ORCID,Breese Erin H.^ORCID,Krupski M. Christa,O'Brien Maureen M.^ORCID,Dandoy Christopher E.,Mizukawa Ben^ORCID,Khoury Ruby,Norris Robin E.,Davies Stella M.,Phillips Christine L.

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference22 articles.

1. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia;Maude;N Engl J Med,2018

2. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL;Curran;Blood,2019

3. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report;Schultz;J Clin Oncol,2022

4. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL;Myers;J Clin Oncol,2022

5. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621;O'Brien;J Clin Oncol,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions;Journal of Hematology & Oncology;2024-05-11

2. INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia;Transplantation and Cellular Therapy;2023-11

3. Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia;European Journal of Haematology;2023-09-29